Your browser doesn't support javascript.
loading
The role of S-nitrosylation of PFKM in regulation of glycolysis in ovarian cancer cells.
Gao, Wenwen; Huang, Mengqiu; Chen, Xi; Chen, Jianping; Zou, Zhiwei; Li, Linlin; Ji, Kaiyuan; Nie, Zhirui; Yang, Bingsheng; Wei, Zibo; Xu, Pengfei; Jia, Junshuang; Zhang, Qianbing; Shen, Hongfen; Wang, Qianli; Li, Keyi; Zhu, Lingqun; Wang, Meng; Ye, Shuangyan; Zeng, Sisi; Lin, Ying; Rong, Zhili; Xu, Yang; Zhu, Peng; Zhang, Hui; Hao, Bingtao; Liu, Qiuzhen.
Afiliación
  • Gao W; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Huang M; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Chen X; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Chen J; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Zou Z; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Li L; Southern Hospital Zengcheng Branch, Southern Medical University, Guangzhou, 528308, China.
  • Ji K; First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan Province, 450001, China.
  • Nie Z; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Yang B; Guangzhou Panyu Central Hospital, Guangzhou, 511400, China.
  • Wei Z; Pearl River Hospital, Southern Medical University, Guangzhou, 528308, China.
  • Xu P; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Jia J; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Zhang Q; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Shen H; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Wang Q; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Li K; Henan Cancer Hospital, Zhengzhou University, Zhengzhou, Henan Province, 450003, China.
  • Zhu L; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Wang M; Guangzhou Concord Cancer Center, Guangzhou, 528308, China.
  • Ye S; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Zeng S; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Lin Y; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Rong Z; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Xu Y; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Zhu P; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Zhang H; The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, 518033, China.
  • Hao B; Central Lab of Shenzhen Pingshan People's Hospital, Shenzhen, 518118, P. R. China.
  • Liu Q; School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, China. hui_zhang0730@hotmail.com.
Cell Death Dis ; 12(4): 408, 2021 04 15.
Article en En | MEDLINE | ID: mdl-33859186
ABSTRACT
One of the malignant transformation hallmarks is metabolism reprogramming, which plays a critical role in the biosynthetic needs of unchecked proliferation, abrogating cell death programs, and immunologic escape. However, the mechanism of the metabolic switch is not fully understood. Here, we found that the S-nitrosoproteomic profile of endogenous nitrogen oxide in ovarian cancer cells targeted multiple components in metabolism processes. Phosphofructokinase (PFKM), one of the most important regulatory enzymes of glycolysis, was S-nitrosylated by nitric oxide synthase NOS1 at Cys351. S-nitrosylation at Cys351 stabilized the tetramer of PFKM, leading to resist negative feedback of downstream metabolic intermediates. The PFKM-C351S mutation decreased the proliferation rate of cultured cancer cells, and reduced tumor growth and metastasis in the mouse xenograft model. These findings indicated that S-nitrosylation at Cys351 of PFKM by NOS1 contributes to the metabolic reprogramming of ovarian cancer cells, highlighting a critical role of endogenous nitrogen oxide on metabolism regulations in tumor progression.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Fosfofructoquinasa-1 Tipo Muscular / Carcinoma Epitelial de Ovario / Glucólisis Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cell Death Dis Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Asunto principal: Fosfofructoquinasa-1 Tipo Muscular / Carcinoma Epitelial de Ovario / Glucólisis Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cell Death Dis Año: 2021 Tipo del documento: Article País de afiliación: China